Estimated Effectiveness of Pfizer-BioNTech COVID-19 Vaccine Against Infection With Delta, Omicron Variants Among Children Ages 5 to 11

JAMA Network Open


Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.


About The Study: The results of this study suggest that among children ages 5 to 11, two doses of the Pfizer-BioNTech COVID-19 vaccine provided modest short-term protection against Omicron infection that was higher for those with prior infection; however, vaccine effectiveness waned after approximately three months in all children. A booster dose restored protection against Omicron and was maintained for at least three months. These findings highlight the continued importance of booster vaccination regardless of history of prior COVID-19. 

Authors: Farid L. Khan, M.P.H., of Pfizer in Collegeville, Pennsylvania, is the corresponding author. 



Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.